1. Home
  2. VERA vs TFIN Comparison

VERA vs TFIN Comparison

Compare VERA & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERA
  • TFIN
  • Stock Information
  • Founded
  • VERA 2016
  • TFIN 1981
  • Country
  • VERA United States
  • TFIN United States
  • Employees
  • VERA N/A
  • TFIN N/A
  • Industry
  • VERA Biotechnology: Pharmaceutical Preparations
  • TFIN Major Banks
  • Sector
  • VERA Health Care
  • TFIN Finance
  • Exchange
  • VERA Nasdaq
  • TFIN Nasdaq
  • Market Cap
  • VERA 2.5B
  • TFIN 2.1B
  • IPO Year
  • VERA 2021
  • TFIN N/A
  • Fundamental
  • Price
  • VERA $42.01
  • TFIN $91.84
  • Analyst Decision
  • VERA Strong Buy
  • TFIN Hold
  • Analyst Count
  • VERA 9
  • TFIN 5
  • Target Price
  • VERA $53.56
  • TFIN $71.80
  • AVG Volume (30 Days)
  • VERA 683.6K
  • TFIN 154.2K
  • Earning Date
  • VERA 11-07-2024
  • TFIN 10-16-2024
  • Dividend Yield
  • VERA N/A
  • TFIN N/A
  • EPS Growth
  • VERA N/A
  • TFIN N/A
  • EPS
  • VERA N/A
  • TFIN 0.80
  • Revenue
  • VERA N/A
  • TFIN $398,012,000.00
  • Revenue This Year
  • VERA N/A
  • TFIN N/A
  • Revenue Next Year
  • VERA N/A
  • TFIN $11.64
  • P/E Ratio
  • VERA N/A
  • TFIN $113.70
  • Revenue Growth
  • VERA N/A
  • TFIN N/A
  • 52 Week Low
  • VERA $9.68
  • TFIN $60.33
  • 52 Week High
  • VERA $50.78
  • TFIN $95.46
  • Technical
  • Relative Strength Index (RSI)
  • VERA 52.57
  • TFIN 70.92
  • Support Level
  • VERA $39.22
  • TFIN $87.69
  • Resistance Level
  • VERA $50.00
  • TFIN $92.37
  • Average True Range (ATR)
  • VERA 2.41
  • TFIN 2.86
  • MACD
  • VERA 0.24
  • TFIN 1.03
  • Stochastic Oscillator
  • VERA 28.53
  • TFIN 99.46

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About TFIN Triumph Financial Inc.

Triumph Financial Inc is a is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Corporate. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The corporate segment includes holding company financing and investment activities and management and administrative expenses to support the overall operations of the Company.

Share on Social Networks: